CA2 and pulmonary arterial hypertension: In a recent study by Wu et al., high-dose dapagliflozin (DAPA) treatment attenuated RV structural remodeling, improved RV function, increased the conduction velocity, restored the expression of key Ca2+ handling proteins, increased the threshold for Ca2+ and action potential duration alternans, decreased susceptibility to spatially discordant action potential duration (APD) alternans and spontaneous Ca2+ events, promoted cellular Ca2+ handling, and reduced VA vulnerability in PAH-induced RHF rats.